Intraocular	intraocular	O	O
pressure	pressure	O	O
in	in	O	O
patients	patients	O	O
with	with	O	O
uveitis	uveitis	O	O
treated	treated	O	O
with	with	O	O
fluocinolone	fluocinolone	B_chemical	O
acetonide	acetonide	I_chemical	O
implants	implants	O	O
.	.	O	O

OBJECTIVE	objective	O	O
:	:	O	O
To	to	O	O
report	report	O	O
the	the	O	O
incidence	incidence	O	O
and	and	O	O
management	management	O	O
of	of	O	O
elevated	elevated	O	O
intraocular	intraocular	O	O
pressure	pressure	O	O
(	(	O	O
IOP	iop	O	O
)	)	O	O
in	in	O	O
patients	patients	O	O
with	with	O	O
uveitis	uveitis	O	O
treated	treated	O	O
with	with	O	O
the	the	O	O
fluocinolone	fluocinolone	B_chemical	O
acetonide	acetonide	I_chemical	O
(	(	O	O
FA	fa	O	O
)	)	O	O
intravitreal	intravitreal	O	O
implant	implant	O	O
.	.	O	O

DESIGN	design	O	O
:	:	O	O
Pooled	pooled	O	O
data	data	O	O
from	from	O	O
3	3	O	O
multicenter	multicenter	O	O
,	,	O	O
double-masked	double-masked	O	O
,	,	O	O
randomized	randomized	O	O
,	,	O	O
controlled	controlled	O	O
,	,	O	O
phase	phase	O	O
2b/3	2b/3	O	O
clinical	clinical	O	O
trials	trials	O	O
evaluating	evaluating	O	O
the	the	O	O
safety	safety	O	O
and	and	O	O
efficacy	efficacy	O	O
of	of	O	O
the	the	O	O
0.59-mg	0.59-mg	O	O
or	or	O	O
2.1-mg	2.1-mg	O	O
FA	fa	O	O
intravitreal	intravitreal	O	O
implant	implant	O	O
or	or	O	O
standard	standard	O	O
therapy	therapy	O	O
were	were	O	O
analyzed	analyzed	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
During	during	O	O
the	the	O	O
3-year	3-year	O	O
follow-up	follow-up	O	O
,	,	O	O
71.0	71.0	O	O
%	%	O	O
of	of	O	O
implanted	implanted	O	O
eyes	eyes	O	O
had	had	O	O
an	an	O	O
IOP	iop	O	O
increase	increase	O	O
of	of	O	O
10	10	O	O
mm	mm	O	O
Hg	hg	O	O
or	or	O	O
more	more	O	O
than	than	O	O
baseline	baseline	O	O
and	and	O	O
55.1	55.1	O	O
%	%	O	O
,	,	O	O
24.7	24.7	O	O
%	%	O	O
,	,	O	O
and	and	O	O
6.2	6.2	O	O
%	%	O	O
of	of	O	O
eyes	eyes	O	O
reached	reached	O	O
an	an	O	O
IOP	iop	O	O
of	of	O	O
30	30	O	O
mm	mm	O	O
Hg	hg	O	O
or	or	O	O
more	more	O	O
,	,	O	O
40	40	O	O
mm	mm	O	O
Hg	hg	O	O
or	or	O	O
more	more	O	O
,	,	O	O
and	and	O	O
50	50	O	O
mm	mm	O	O
Hg	hg	O	O
or	or	O	O
more	more	O	O
,	,	O	O
respectively	respectively	O	O
.	.	O	O

Topical	topical	O	O
IOP-lowering	iop-lowering	O	O
medication	medication	O	O
was	was	O	O
administered	administered	O	O
in	in	O	O
74.8	74.8	O	O
%	%	O	O
of	of	O	O
implanted	implanted	O	O
eyes	eyes	O	O
,	,	O	O
and	and	O	O
IOP-lowering	iop-lowering	O	O
surgeries	surgeries	O	O
,	,	O	O
most	most	O	O
of	of	O	O
which	which	O	O
were	were	O	O
trabeculectomies	trabeculectomies	S_chemical	O
(	(	O	O
76.2	76.2	O	O
%	%	O	O
)	)	O	O
,	,	O	O
were	were	O	O
performed	performed	O	O
on	on	O	O
36.6	36.6	O	O
%	%	O	O
of	of	O	O
implanted	implanted	O	O
eyes	eyes	O	O
.	.	O	O

Intraocular	intraocular	O	O
pressure-lowering	pressure-lowering	O	O
surgeries	surgeries	O	O
were	were	O	O
considered	considered	O	O
a	a	O	O
success	success	O	O
(	(	O	O
postoperative	postoperative	O	O
IOP	iop	O	O
of	of	O	O
6	6	O	O
-	-	O	O
21	21	O	O
mm	mm	O	O
Hg	hg	O	O
with	with	O	O
or	or	O	O
without	without	O	O
additional	additional	O	O
IOP-lowering	iop-lowering	O	O
medication	medication	O	O
)	)	O	O
in	in	O	O
85.1	85.1	O	O
%	%	O	O
of	of	O	O
eyes	eyes	O	O
at	at	O	O
1	1	O	O
year	year	O	O
.	.	O	O

The	the	O	O
rate	rate	O	O
of	of	O	O
hypotony	hypotony	S_chemical	O
(	(	O	O
IOP	iop	O	O
<	<	O	O
/=	/=	O	O
5	5	O	O
mm	mm	O	O
Hg	hg	O	O
)	)	O	O
following	following	O	O
IOP-lowering	iop-lowering	O	O
surgery	surgery	O	O
(	(	O	O
42.5	42.5	O	O
%	%	O	O
)	)	O	O
was	was	O	O
not	not	O	O
different	different	O	O
from	from	O	O
that	that	O	O
of	of	O	O
implanted	implanted	O	O
eyes	eyes	O	O
not	not	O	O
subjected	subjected	O	O
to	to	O	O
surgery	surgery	O	O
(	(	O	O
35.4	35.4	O	O
%	%	O	O
)	)	O	O
(	(	O	O
P	p	O	O
=	=	O	O
.09	.09	O	O
)	)	O	O
.	.	O	O

CONCLUSION	conclusion	O	O
:	:	O	O
Elevated	elevated	O	O
IOP	iop	O	O
is	is	O	O
a	a	O	O
significant	significant	O	O
complication	complication	O	O
with	with	O	O
the	the	O	O
FA	fa	O	O
intravitreal	intravitreal	O	O
implant	implant	O	O
but	but	O	O
may	may	O	O
be	be	O	O
controlled	controlled	O	O
with	with	O	O
medication	medication	O	O
and	and	O	O
surgery	surgery	O	O
.	.	O	O

